ATTR-CM Incidence, Prevalence Rose Sharply in the US

The incidence and prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) increased markedly in the US between 2010 and 2023, according to a study published in the Journal of the American Heart Association.1 The findings, drawn from 2 large claims databases, provide updated epidemiologic estimates from large US insurance claims databases.

“Advances in diagnosis and disease awareness have led to increased prevalence and incidence of transthyretin amyloid cardiomyopathy (ATTR‐CM), but current US population‐based epidemiologic data are lacking,” wrote the researchers of the study. “This study aimed to estimate temporal trends and current prevalence and incidence of ATTR‐CM in the United States and to describe patient characteristics and the clinical burden.”